Physician profile
James P Colvard
NPI 1225312432
$1,259.97
in general payments reported to CMS, 2019-2025
15 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.84 · 2021: $116 · 2022: $663 · 2023: $111 · 2024: $121 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.63 | 2022-2024 | |
| Novo Nordisk INC | $209.57 | 2022-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $150.94 | 2021-2022 | |
| Boston Scientific Corporation | $125.53 | 2022-2025 | Enroute Transcarotid Neuroprotection System |
| Glaxosmithkline, LLC. | $124.31 | 2022 | |
| Pfizer INC. | $102.79 | 2022-2025 | |
| Ibsa Pharma INC. | $42.33 | 2022 | |
| Dexcom, INC. | $42.02 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $39.02 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $36.03 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Amgen INC. | $29.23 | 2022 | |
| Abbott Laboratories | $22.39 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2022 | |
| Pulmonx Corporation | $16.49 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Medtronic Vascular, INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Colvard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.